Randomized Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin With or Without Durvalumab (MEDI4736) Followed by Postoperative Durvalumab (MEDI4736) in Patients With Localized Biliary Tract Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Cisplatin; Gemcitabine
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
Focus Therapeutic Use
Acronyms DEBATE

Most Recent Events

28 Jan 2025 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
15 Jan 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
24 Oct 2023 Results assessing the efficacy of neoadjuvant durvalumab plus gemcitabine and cisplatin versus gemcis alone for localized biliary tract cancer, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight